154 related articles for article (PubMed ID: 32574826)
1. The treament of hyperglycemia in acute ischemic stroke with incretin-based drugs.
Ferrari F; Moretti A; Villa RF
Pharmacol Res; 2020 Oct; 160():105018. PubMed ID: 32574826
[TBL] [Abstract][Full Text] [Related]
2. Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives.
Ferrari F; Moretti A; Villa RF
Pharmacol Ther; 2022 Nov; 239():108277. PubMed ID: 36064147
[TBL] [Abstract][Full Text] [Related]
3. [Modulation of the incretin effect in the treatment of diabetes].
Vidal J
Med Clin (Barc); 2014 Sep; 143 Suppl 2():8-11. PubMed ID: 25437459
[TBL] [Abstract][Full Text] [Related]
4. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
Gallwitz B
Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
[TBL] [Abstract][Full Text] [Related]
5. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
7. [Modulation of the incretin effect in the treatment of diabetes].
Vidal J
Med Clin (Barc); 2014; 143 Suppl 2():8-11. PubMed ID: 25326837
[TBL] [Abstract][Full Text] [Related]
8. Use of incretin-based therapy in hospitalized patients with hyperglycemia.
Umpierrez GE; Schwartz S
Endocr Pract; 2014 Sep; 20(9):933-44. PubMed ID: 25100362
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapy of hyperglycemia.
Kulasa KM; Henry RR
Expert Opin Pharmacother; 2009 Oct; 10(15):2415-32. PubMed ID: 19743938
[TBL] [Abstract][Full Text] [Related]
10. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
Blonde L; Montanya E
Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
[TBL] [Abstract][Full Text] [Related]
11. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
Nauck M
Diabetes Obes Metab; 2016 Mar; 18(3):203-16. PubMed ID: 26489970
[TBL] [Abstract][Full Text] [Related]
12. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
13. [Characteristics and types of GLP-1 receptor agonists. An opportunity for individualized therapy].
Jódar E
Med Clin (Barc); 2014 Sep; 143 Suppl 2():12-7. PubMed ID: 25437460
[TBL] [Abstract][Full Text] [Related]
14. Gliptin-mediated neuroprotection against stroke requires chronic pretreatment and is independent of glucagon-like peptide-1 receptor.
Darsalia V; Larsson M; Lietzau G; Nathanson D; Nyström T; Klein T; Patrone C
Diabetes Obes Metab; 2016 May; 18(5):537-41. PubMed ID: 26847506
[TBL] [Abstract][Full Text] [Related]
15. Blood pressure-lowering effects of incretin-based diabetes therapies.
Lovshin JA; Zinman B
Can J Diabetes; 2014 Oct; 38(5):364-71. PubMed ID: 25284699
[TBL] [Abstract][Full Text] [Related]
16. Incretin-based therapies: where will we be 50 years from now?
Meier JJ; Nauck MA
Diabetologia; 2015 Aug; 58(8):1745-50. PubMed ID: 25994073
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
Pratley RE; Salsali A
Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
[TBL] [Abstract][Full Text] [Related]
18. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs.
Mentlein R
Expert Opin Investig Drugs; 2005 Jan; 14(1):57-64. PubMed ID: 15709922
[TBL] [Abstract][Full Text] [Related]
20. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]